Preclinical screening of compounds

The Preclinical Testing Core (PTC) of the MODEL-AD) consortium supports preclinical screening of test compounds nominated by the greater research community. The PTC has established a streamlined preclinical drug testing strategy with go/no-go decision points that...

MODEL-AD Presentations at SfN 2019

Monday, October 21, 2019 Session #354 – 4:15-4:30 PM - McCormick Place: Room S103 Title: Developing mouse models to study late-onset Alzheimer’s Disease D. BAGLIETTO-VARGAS1,2, L. CAI1, M. NGUYEN1, K. HUYNH1, A.C. MARTINI1, L. TRUJILLO-ESTRADA1, C. SOTO3, I....

MODEL-AD Presentations at AAIC 2019

Sunday, July 14, 4:55-5:15 PM, Petree Hall C #F1-07-03 Alzheimer’s Susceptibility Genes Implicate Microglial Activity Julie Williams, PhD1,2; Rebecca Sims, PhD3; Philip Taylor, PhD2; Michael Sasner, PhD4; Harriet M Williams, MPhil4 and Gareth Howell, PhD3,4, (1)UK...

nanoString Webinar Thursday, 3/14/19

A gene expression-based screening platform for mouse models of late-onset Alzheimer's disease When: Thursday, March 14, 9:00 a.m. PT Speaker: Greg Carter, PhD, Associate Professor, The Jackson Laboratory Late-onset Alzheimer’s disease (LOAD) is the most common form of...

Skip to toolbar